BBIO · BridgeBio Pharma Inc
United States · RS rating 25 · As of 2026-10-14
| Price | 64.94 USD |
|---|---|
| 1-day change | +2.6% |
| RS rating (overall / 1M / 3M / 12M) | 25 / 37 / 20 / 69 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 37 / 12 / 34 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -5.3% |
| Sales growth Q/Q | +27.7% |
| Distance from 52-week high | +28.0% |
| Market cap (USD) | $13.9B |